PRLD (Prelude Therapeutics) Ending Cash Position: $24.99 Mil (As of Mar. 2026)


PRLD Prelude Therapeutics Inc PRLD
26 GF Score
Price $4.99
! 6 Warning Signs
View Full Analysis

What is Prelude Therapeutics Ending Cash Position?

Prelude Therapeutics PRLD +1.63% 26 Ending Cash Position is $24.99 Mil as of Mar. 2026. GuruFocus rates PRLD with a GF Score™ of 26/100. The stock has 6 warning signs investors should review.

Prelude Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $24.99 Mil.

Prelude Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 ($50.77 Mil) to Dec. 2025 ($38.49 Mil) and declined from Dec. 2025 ($38.49 Mil) to Mar. 2026 ($24.99 Mil).

Prelude Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($29.34 Mil) to Dec. 2024 ($16.52 Mil) but then increased from Dec. 2024 ($16.52 Mil) to Dec. 2025 ($38.49 Mil).

Prelude Therapeutics Ending Cash Position Related Terms

Prelude Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Prelude Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prelude Therapeutics Ending Cash Position Chart

Prelude Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 35.87 34.65 29.34 16.52 38.49

Prelude Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.31 29.80 50.77 38.49 24.99
PRLD
26GF Score
Prelude Therapeutics Inc PRLD
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prelude Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Prelude Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=16.518+21.973
=38.49

Prelude Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=38.491+-13.5
=24.99

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $24.99 Mil mean?
Prelude Therapeutics (PRLD) has a Ending Cash Position of $24.99 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Prelude Therapeutics and its competitors.
Is Prelude Therapeutics' Ending Cash Position too high?
Prelude Therapeutics' current Ending Cash Position is $24.99 Mil. Overall, Prelude Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Ending Cash Position compare to DMAC and RCKT?
Prelude Therapeutics' Ending Cash Position of $24.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Prelude Therapeutics and its competitors. Prelude Therapeutics's current Ending Cash Position is $24.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Ending Cash Position of $24.99 Mil. The current Ending Cash Position is $24.99 Mil. Prelude Therapeutics' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Ending Cash Position is $24.99 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prelude Therapeutics Business Description

Address 175 Innovation Boulevard, Wilmington, DE, USA, 19805
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
26GF Score

Get the complete analysis for PRLD

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.99
Price